user

ANTIPROTEINURIC EFFECTS OF A SWITCHED THERAPEUTIC REGIMEN BASED ON IRBESARTAN ALONE OR IN COMBINATION WITH ALISKIREN IN OVERT DIABETIC NEPHROPATHY

被引：0
|
作者：
Aranda, P. [1 ]
Cobelo, C. [1 ]
Jironda, C. [1 ]
Fernandez-Garcia, J. C. [2 ]
Martinez, M. D. [1 ]
Frutos, M. A. [1 ]
机构：
[1] Carlos Haya Univ Hosp, Dept Hypertens & Nephrol, Malaga, Spain
[2] Carlos Haya Univ Hosp, Dept Endocrinol, Malaga, Spain
来源：
JOURNAL OF HYPERTENSION | 2010年 / 28卷
关键词：
D O I：
10.1097/01.hjh.0000379068.15513.f8
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：E293 / E293
页数：1
相关论文
共 9 条
  • [1] Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy
    Kuriyama, S
    Tomonari, H
    Tokudome, G
    Horiguchi, M
    Hayashi, H
    Kobayashi, H
    Ishikawa, M
    Hosoya, T
    [J]. HYPERTENSION RESEARCH, 2002, 25 (06) : 849 - 855
  • [2] Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats
    Eren, Zehra
    Gunal, Mehmet Yalcin
    Bakir, Elif Ari
    Coban, Jale
    Caglayan, Berrak
    Ekimci, Nur
    Ethemoglu, Sinem
    Albayrak, Ozgur
    Akdeniz, Tuba
    Demirel, Gulderen Yanikkaya
    Kilic, Ertugrul
    Kantarci, Gulcin
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2014, 39 (06): : 581 - 590
  • [3] The Renal and Cardio Protective Effects of Aliskiren and Pentoxifylline Alone and in Combination on Streptozotocin Induced Diabetic Rats
    El-Mahdy, Nageh A.
    El-Masry, Thanaa A.
    El-Desouky, Karima I.
    Ghanem, Sahar K.
    [J]. BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 12 (01):
  • [4] Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
    Abdel-Wahab, Ali F.
    Bamagous, Ghazi A.
    Al-Harizy, Randa M.
    ElSawy, Naser A.
    Shahzad, Naiyer
    Ibrahim, Ibrahim A.
    Al Ghamdi, Saeed S.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 59 - 66
  • [5] A three years renoprotective effect of a multifactorial Irbesartan 600 mg-based treatment in patients with overt diabetic nephropathy
    Aranda, P.
    Fernandez, J.
    Martinez, D.
    Gomez, P.
    Segura, J.
    Franquelo, R.
    Ruilope, L.
    [J]. JOURNAL OF HYPERTENSION, 2008, 26 : S189 - S189
  • [6] Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy
    Elrashidy, Rania A.
    Asker, Mervat E.
    Mohamed, Hoda E.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (06) : 862 - 871
  • [7] Clinical Trial Design Based on Disease Progression and Pharmacological Effects in the Irbesartan Diabetic Nephropathy Trial (IDNT)
    Chan, Phyllis
    Chen, Chunlin
    Clawson, David
    Soares, Holly
    Pupim, Lara
    LaCreta, Frank
    AbuTarif, Malaz
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S113 - S113
  • [8] Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolopril (T) or calcium antagonist, verapamil (V) alone or in fixed dose combination in patients with diabetic nephropathy: A randomized multicenter study.
    Bakris, GL
    Weir, M
    DeQuattro, V
    Rosendorff, C
    McMahon, G
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A1479 - A1479
  • [9] Effects of HuoxueJiangtang decoction alone or in combination with metformin on renal function and renal cortical mRNA expression in diabetic nephropathy rats
    Liu, Xuemei
    Liu, Deliang
    Shuai, Youyou
    Li, Huilin
    Zhao, Hengxia
    Qu, Xin
    Chu, Shufang
    Zhang, Xuewen
    [J]. PHARMACEUTICAL BIOLOGY, 2020, 58 (01) : 1123 - 1130
1